This document can be used to prepare or evaluate feasibility of ancillary study proposals and paper proposals, but is NOT intended for publication.
Specimen Assay Results
File Name
Data as of
Population
Data collected
One row per
Rows
spec_results_ctos_inv.dat
3/14/2023
CT+OS
Baseline, Main, Ext1, Ext2
Specimen Test Result
3,364,747
This file contains results from WHI core and ancillary studies. These results are provided ""as is"". Some of these tests may have QA issues and often there may be significant normalization work required when combining results from multiple studies/labs/specimen types. See the data->Specimen result page at www.whi.org for a discussion of WHI specimen testing and QA procedures as well as summary result and QA statistics by test version and pull.
ID - WHI Participant Common ID
Col 1
N
Missing
Min
Max
Mean
StdDev
3,364,747
0
100,001
299,999
199,914.946
57,714.218
PPTDRW - Participant Draw Number
Col 2
ID and PPTDRW identify a specimen draw.
Usage Notes:
Use ID and PPTDRW to merge with the specimen draws file (spec_draws) or the specimen results file (spec_results).
N
Missing
Min
Max
Mean
StdDev
3,364,747
0
1
13
1.63
1.065
TESTVERID - Test version ID
Col 3
Unique identifier of the test name and test version.
N
Missing
Min
Max
Mean
StdDev
3,364,747
0
1
35,850
15,629
14,190.238
STUDYID - Study ID
Col 4
Value
Description
N
%
105
Carotenoids in age-related eye disease study (CAREDS)
49,702
1.5
110
Sex hormones and CHD
20,725
0.6
121
Hyperinsulinemia and ovarian cancer
2,190
0.1
126
Stroke risk factors and molecular markers
77,300
2.3
129
Diabetes+IGF-I in colorectal,breast,endometrial caner
15,196
0.5
132
Genetic and biochemical predictors of type 2 diabetes
30,137
0.9
133
Predictors of hypertension in white and black women
14,207
0.4
134
Estrone, HRT, and breast cancer
810
0
146
A prospective study of pancreatic cancer pathogenesis
6,404
0.2
165
Thyroid dysfunction and MI/stroke risk
5,378
0.2
167
Sex hormones and ER+/ER- breast cancer
6,221
0.2
179
Frailty in WHI: drugs, inflammatory and genetic markers
10,814
0.3
181
Hip fracture estradiol, cytokines, bone turnover
5,566
0.2
187
Serum fatty acids and incidence of ischemic stroke in women
56,115
1.7
189
Biochemical & anthropometric measures among obese
35,392
1.1
191
Biomarkers & genetic factors rel. to sarcopenia (with as199)
99,043
2.9
195
Candidate pathways in colorectal carcinogenesis
28,926
0.9
206
Selenium and colorectal cancer
1,701
0.1
207
IGF and multiple myeloma
4,085
0.1
208
Pro and anti-inflammatory cytokines and colorectal cancer
8,018
0.2
214
Prospective cohort in pancreatic cancer (AS146 extension)
9,723
0.3
238
Biochemical predictors of type 2 diabetes mellitus in women
9,702
0.3
242
DNA repair, telomere length and melanoma
942
0
254
Liu/Telomere/diabetes
4,029
0.1
266
EGFR-signaling-network activators/inhibitor & lung ca
20,685
0.6
275
Urinary levels of melatonin and risk of breast cancer
1,557
0
282
Serum markers for multi-stage ovarian cancer screening
19,271
0.6
284
Obesity/Breast Disease
8,149
0.2
290
Cadmium Exposure and Risk of Breast Cancer
54,288
1.6
292
Advanced Glycation End Products,receptor and Colorectal Ca
2,058
0.1
294
Lung CA & one-carbon metabolis
21,291
0.6
296
Cohort study of etiology of hepatocellular carcinoma
2,160
0.1
297
Estrogens, estr. metabolites & androgens/endo & ovarian ca
59,273
1.8
321
Estrogen DNA adducts: estrogen biomarker and breast cancer
40,404
1.2
325
Ethnic Differences in 25(OH)D and PTH Levels and CVD
34,030
1
327
Vit D/Lung Ca/never smoking
6,509
0.2
332
AVIIR score in predicting incident CHD
19,187
0.6
346
Serum, vitamin D, and risk of melanoma in WHI-OS
3,236
0.1
362
Glycation/obesity/pancreatic C
7,396
0.2
374
HPV /head and neck cancer
16,769
0.5
383
VitD/BR and Colorectal Ca
58
0
389
Multiple myeloma/adipo levels
1,182
0
402
Biomarkers and risk of ALS
18,405
0.5
403
Systemic and breast-cancer specific autoimmunity in the WHI
839
0
411
Excess mortality in women with rheumatoid arthritis
HRT, estrogen metabolism and breast cancer or hip fracture
8,447
0.3
BA13
B-cell stimulation markers and non-Hodgkins lymphoma
20,564
0.6
BA18
Followup studies of genetically determined risk factors
3,723
0.1
BA20
Arthritis, inflammation, thrombogenesis and CVD/mortality
159,465
4.7
BA21
Understanding the role of sex hormones in colorectal cancer
10,524
0.3
BA22
Predictive modeling for CVD in a multiethnic cohort in women
39,798
1.2
BA25
Leukocyte Telomere Dynamics
5,201
0.2
BA6
Inflamation genes, diet, medication, and cancer
7,862
0.2
BA7
Estradiol/estrogen and CHD, fx, stroke, VTE, cog imp.
14,239
0.4
BA8
Predictive value of nutrient biomarkers for CHD death
12,176
0.4
BA9
Biochemical antecedents of fracture in minority women
38,142
1.1
M11
NCI - Upper GI cancer GWAS and telomere length
2,640
0.1
W1
CT 6% Subsample, Clinic CBCs, QC Pools
1,275,669
37.9
W10
Biological markers of the effect of HT on breast cancer
23,316
0.7
W11
CVD biomarkers - Phase II: strokes after Feb. 2001
8,689
0.3
W14
CVD biomarkers - Phase I: additional assays
18,632
0.6
W15
Vit D and colorectal cancer or fractures in CaD trial
3,635
0.1
W18
HT Hormone Pretest
2,877
0.1
W2
OS-measurement precision study (OS-MPS)
38,990
1.2
W22
Vitamin D levels in 6% blood subsample of CaD
1,198
0
W24
Vitamin D and breast cancer in CaD trial
2,161
0.1
W27
NPAAS lab work
5,863
0.2
W39
27-hydroxycholesterol in CVD biomarkers (W-6)
1,163
0
W45
Proteomic Colon Cancer Study
1,840
0.1
W5
Endogenous sex hormones in DM trial
7,257
0.2
W54
CVD Biomarkers for 2010-2015 (SHARe cohort only)
95,262
2.8
W57
HT Proteomics on B2M and IGFBP4
1,217
0
W58
CVD, diabetes, and renal biomarkers in the EA HT Cohort
80,772
2.4
W6
HT CVD Biomarkers: study of CHD, Stroke and VTE - Phase I
116,930
3.5
W64
Long Life Study (LLS)
250,542
7.4
W66
Long Life Study-Phase III Biomarkers and GWAS
11,845
0.4
W8
Nutritional biomarkers study (NBS)
3,924
0.1
W9
Sex hormones and fractures
5,766
0.2
83
Thrombotic, inflammatory and genetic markers for CHD
6,877
0.2
90
WHI sex hormone and genetic risk factors for hip fracture
10,583
0.3
97
Ovarian cancer serum markers
2,787
0.1
TESTVAL - Test Result Value
Col 5
N
Missing
Min
Max
Mean
StdDev
3,364,747
0
-776
171,000,000
42,150.518
1,205,817.722
TESTDY - Test Days Since Draw
Col 6
Number of days from date of specimen draw to when the specimen was sent to the lab for testing.
N
Missing
Min
Max
Mean
StdDev
3,358,136
6,611
1
9,402
4,291.212
2,213.661
PULLID - Study pull id
Col 7
The id of the study pull responsible for the test result. Pull ids are in the form xxx-yyy where xxx is the study id.
Usage Notes:
A "pull" is a set of vials pulled from the repository and shipped to one or more lab(s). A study will often have several pulls even if they only use a single lab. Multiple pulls are created to control workload and to limit the damage in case of shipping errors. Summary statistics for assays by pull can be found at www.whi.org in the specimen results page of the WHI data section.
This file contains results from WHI core and ancillary studies. These results are provided ""as is"". Some of these tests may have QA issues and often there may be significant normalization work required when combining results from multiple studies/labs/specimen types. See the data->Specimen result page at www.whi.org for a discussion of WHI specimen testing and QA procedures as well as summary result and QA statistics by test version and pull.